ProCE Banner Activity


Practical Insights and Management: Hepatitis Delta in Focus


In this case-based video module, expert faculty share their approach to managing HDV, including considerations for treatment initiation and duration of current and novel therapies, as well as practical considerations such as hepatocellular carcinoma screening and other key monitoring parameters.

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Nurses: 0.50 Nursing contact hour

Released: May 11, 2023

Expiration: May 10, 2024

No longer available for credit.



Ira Jacobson

Ira Jacobson, MD

Professor of Medicine
Director of Hepatology
NYU Langone Health
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from Gilead Sciences, Inc. and Janssen Therapeutics, Division of Janssen Products, LP.

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Target Audience

This program is intended for physicians, pharmacists, registered nurses, nurse practitioners, and other healthcare professionals who provide care for patients with HDV infection or patients at risk for HBV/HDV infection.

Program Learning Goal

To increase awareness of hepatitis delta virus among specialist and nonspecialist multiprofessional audiences and to provide key action steps to improve screening, diagnosis, linkage to care, and management of HDV

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recount key safety and efficacy data from clinical trials of new and investigational therapies for chronic HDV infection
  • Apply best practices in the practical implementation of treatment for HDV


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Ira Jacobson, MD

Professor of Medicine
Director of Hepatology
NYU Langone Health
New York, New York

Ira Jacobson, MD: consultant: Aligos, Arbutus, Gilead Sciences, Intercept, Merck, Roche; researcher: Assembly, Cymabay, Eiger, Galectin, Genfit, Genkyotex, GlaxoSmithKline, Intercept, Janssen, Lilly, Mirum, Novo Nordisk; data monitoring committee: Altimmune, GlaxoSmithKline, Takeda. 

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from May 11, 2023, through May 10, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Continuing Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.50 contact hours.


Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-133-H01-P
Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.